Direct-Acting Oral Anticoagulants: A Comparative Study on Value and Pricing

By Staff Writer

October 6, 2023

The Inflation Reduction Act (IRA) has initiated a new era in drug pricing. Soon, the Centers for Medicare & Medicaid Services (CMS) in the U.S will negotiate prices for certain high-cost drugs. This includes direct-acting oral anticoagulants (DOACs) apixaban (Eliquis) and rivaroxaban (Xarelto). These were among the first 10 drugs selected for negotiation.

Clinical and Economic Comparisons

The Institute for Clinical and Economic Review (ICER) released a Special Report that examines these two drugs, primarily used for non-valvular atrial fibrillation (NVAF). They were compared to warfarin, the older standard therapy, and dabigatran, the first DOAC available as a generic medication. The study considered patient experiences, clinical effectiveness, and cost comparisons.

The findings indicate that DOACs improve outcomes for NVAF patients compared to warfarin. Both apixaban and rivaroxaban have shown small net benefits compared to warfarin. However, when compared to dabigatran, the benefits are comparable or small.



Considering the Pricing Aspect

To inform drug price negotiations, they have calculated price premiums at various cost-effectiveness thresholds for apixaban and rivaroxaban relative to warfarin and dabigatran. For instance, the annual price premium for apixaban relative to warfarin ranges from $1,260 at a threshold of $50,000/evLYG to $4,350 at $200,000/evLYG. However, rivaroxaban was not associated with health gains compared to dabigatran. Thus, not supporting a price premium above CMS pricing for dabigatran.

This information provides a foundation for CMS and other stakeholders to make informed decisions about the value and pricing of these important drugs.

Reference url

Recent Posts

Enhertu reimbursement analysis
                 

Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges

💡 How do we balance groundbreaking cancer treatments with budget realities?

The recent analysis by the Dutch Healthcare Institute on Enhertu shines a light on the complexities of integrating innovative therapies for HER2-low metastatic breast cancer into national insurance packages. While the clinical efficacy is evident, the substantial cost implications and demand for steep price reductions bring significant challenges to market access.

Explore the nuances of this vital discussion on clinical effectiveness, economic evaluation, and the future of pricing strategies in oncology.

#SyenzaNews #HealthEconomics #MarketAccess

drug price comparison
 

Global Drug Price Gaps Demand Better Drug Pricing Analysis

💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.

But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?

Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.

#SyenzaNews #healthcare #pricing

NICE HealthTech Reforms
            

NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global Healthcare Systems

🌐 Are you ready to witness a paradigm shift in digital health technology?

The National Institute for Health and Care Excellence (NICE) has announced transformative reforms aimed at accelerating the adoption of digital health innovations within the NHS. By focusing on cost-effectiveness rather than mere cost savings, these changes promise to streamline regulatory processes and enhance evaluations aligned with healthcare priorities.

Dive into this insightful article to explore how NICE’s reforms could reshape the future of healthcare systems globally!

#SyenzaNews #DigitalHealth #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.